Blog

Indira DAVID, Research scientist in our team, just published in Hippocampus a paper showing the versatility of doublecortin expression in the dentate gyrus of adult hippocampus. This « so-called » marker of neuronal maturation, a step of adult hippocampal neurogenesis, may be over-expressed even when there is no increase in Neurogenesis. Congrats to Indira for this long…
Lire la suite

Yann Pelloux is the winner of the Junior Professor Chair (JPC) of the MOODS team of the Centre de Recherche en Epidémiologie et Santé des Populations (CESP Inserm/UVSQ/UPSaclay). His specialization in cognitive processes will complete the range of clinical and preclinical approaches implemented in the team. During his training, his research activities have evolved from…
Lire la suite

Indira DAVID, Research scientist in our team is one of the winners of the prestigious « 2022 National Alliance for Research on Schizophrenia and Depression Young Investigator award » given by the American « Brain & Behavior Research Foundation ». The NARSAD Young Investigator award is one of the highest honors in the field of mental health research. It…
Lire la suite

Four scientists at Columbia University Vagelos College of Physicians and Surgeons have received awards from the Schaefer Research Scholars Program, made possible through a bequest from Dr. Ludwig Schaefer. Each award consists of a $50,000 cash prize and up to $200,000 in direct research support. Pr David is a visiting faculty who iscollaborating with VP&S faculty.…
Lire la suite

This review describes (R,S)-ketamine pharmacodynamics and pharmacokinetics to alert clinicians about possible drug-drug interactions during a concomitant administration of (R,S)-ketamine and CYP inducers/inhibitors that could enhance or blunt, respectively, (R,S)-ketamine’s therapeutic antidepressant efficacy in patients. https://pubmed.ncbi.nlm.nih.gov/34965407/

In our study, patients who were homozygous carriers of the variant G of the HTR4 rs1345697 had lower depressive symptoms improvement and 2-fold lower remission rates after antidepressant treatment as compared to allele A carriers. Randomization study should be done to confirm these results. https://pubmed.ncbi.nlm.nih.gov/34906639/

Our data suggest a decreased mitochondrial metabolism of l-carnitine into ALC during MDE. This decreased mitochondrial metabolism is restored after a 6-month antidepressant treatment. Moreover, the magnitude of mitochondrial dysfunction may predict remission after 3 months of antidepressant treatment. New strategies targeting mitochondria should be explored to improve treatments of MDD. https://pubmed.ncbi.nlm.nih.gov/35115069/

Recent contradictory data has renewed discussion regarding the existence of adult hippocampal neu- rogenesis (AHN) in humans, i.e., the continued production of new neurons in the brain after birth. The present review revisits the debate of AHN in humans from a historical point of view in the face of con- tradictory evidence, analyzing the methods employed…
Lire la suite

In a collaborative paper with the Perception and Memory Unit at the Institut Pasteur, the Department of Epidemiology and Population Health, American University of Beirut and the Smell and Taste Clinic in TU Dresden (Germany), the Moods team showed that the olfactory dysfunctions associated with major depression are uncorrelated with the depression severity but that…
Lire la suite

To read this week: a paper co-authored by researchers from the MOODS team: the role of sex and ovarian hormones on the effect of certain anti-depressants (Ketamine) in mice. How using an animal model sheds light on a social issue, i.e. the effect of sex on treatment in medicine and psychiatry in particular. https://pubmed.ncbi.nlm.nih.gov/32417852/